

Dr Hugo Charles Turner

Website: <http://www.oucru.org/dr-hugo-turner/>

Telephone: 07789444987

E-mail: hugo.turner@ndm.ox.ac.uk

Research Summary

My research focuses on health economic analyses of infectious diseases in low and middle-income countries. I specialize and have extensive experience in performing costings of healthcare interventions, cost of illness analysis and cost-effectiveness analysis. I work on projects on a wide range of infectious diseases (including neglected tropical diseases, dengue, HCV, HPV, hospital-acquired infections, and tetanus). I have conducted fieldwork in Ghana and Kenya and was based at a research unit in Vietnam for over three years. Unlike many health economists, I am also highly trained in dynamic transmission modelling. The goal of my research career is to use health economics to help optimise healthcare policy in low and middle-income countries.

My current role is to **establish and lead a health economics group** within the Oxford University Clinical Research Unit, building in-house capacity to design and perform health economic analyses. Specifically, my role involves:

- Leading the economic analysis for various trials and projects.
- Providing health economic **teaching, training and support**.
- Supervising **two Research Assistants**.
- Contributing to research grants.
- Developing and leading the unit's health economics research agenda.

Research Roles

- August 2016 to present: **Lead Health Economist**, Oxford University Clinical Research Unit, Centre for Tropical Medicine (OUCRU), University of Oxford (based in Vietnam)
- December 2013 to July 2016: **Research Associate and Research Stream Leader for Health Economics, London Centre for Neglected Tropical Disease Research** – based at Imperial College London
- April 2013 to December 2013: **Mathematical Modelling Consultant**, The Onchocerciasis Vaccine for Africa Initiative

Qualifications

- PhD: Infectious Disease Epidemiology (The impact and cost of ivermectin control strategies against River Blindness), Imperial College London (October 2010 to May 2014)
- MSc: Modern Epidemiology (Merit), Imperial College London (2009-2010)
- BSc: Honours Biology (2.1), Imperial College London (2006-2009)

Professional Achievements

- Member of the Wellcome Trust's **Policy Engagement Network** (2018-ongoing).
- A **Global Assessor** for the Royal Society of Tropical Medicine and Hygiene.
- Invited speaker at the '**All-Party Parliamentary Group for Malaria and Neglected Tropical Diseases (NTDs)**', Translating NTD Research into Policy' event (2018).
- Member of the **Scientific Committee for the 2018** annual meeting of the International Society for Economics and Social Sciences of Animal Health (ISESSAH).
- **Invited participant and speaker at the 2016 WHO Guideline Development Group meeting for deworming.**
- **Guest Editor** for PLoS NTD's (2015-present) and for a special issue on Global Infectious Diseases and Response Systems in BioMed Research International (2018-ongoing).
- Reviewer for The Lancet, BMJ Global Health, Campbell Collaboration, PLoS NTD's and PLoS ONE, Parasitology.
- Co-chair of a scientific session entitled "Soil-transmitted Intestinal and Tissue Helminths: Epidemiology and control" at the ASTMH (2015) conference.
- Participant of the Technical Advisory Group for the "Eradication Investment Cases for Onchocerciasis, Lymphatic Filariasis, and Human African Trypanosomiasis" project at Swiss TPH (2013-2014).

Supervisory Experience

- **2017-ongoing: Primary supervisor** to two Research Assistants within the health economic group at the Oxford University Clinical Research Unit.
 - **One of which is currently transitioning into a PhD student (I am the primary supervisor).**
- **2018: Primary supervisor** for an MSc International Health and Tropical Medicine (University of Oxford) entitled "Estimating the Pre-control Global Economic Burden of Lymphatic Filariasis".
- **2016: Primary supervisor** on a BSc Biology student summer dissertation (Imperial College London) entitled "Lymphatic Filariasis: A Systematic Review of the Economic Evaluations of Lymphatic Filariasis Interventions".
- **2014-2016: Co-supervisor for three Research Assistants** within the NTD Epidemiology Research Group at Imperial College London.

Teaching

- **May 2019:** Organising and leading a three-day health economic training workshop in Ho Chi Minh City, Vietnam. We had over 90 applications to attend the course.
- **2017-ongoing:** Running health economics training workshops within OUCRU. This consists of an introductory lecture, "Introduction to health economics", and three interactive workshops on: "Effectiveness metrics", "Cost of illness analysis" and "Cost-effectiveness analysis". These are specifically designed to be relevant for those working in low and middle-income countries. I have given these across the OUCRU network in Ho Chi Minh City, Hanoi and Indonesia.
- **2018-ongoing:** Providing a lecture within the health economic module of the InterRisk MSc (CIRAD) in Bangkok, Thailand.
- **2017-ongoing:** Providing health economics lectures within Oxford's International Health and Tropical Medicine MSc (12 hours per year).
- **2017:** Provided a lecture on cost of illness analysis within a Pasteur Institute Health Economics workshop in Ho Chi Minh City.

- **2017:** Provided health economics lectures (3 hours) within an **Introduction to Infectious Disease Modelling workshop** at the Christian Medical College Vellore, India and lectured (1.5 hours) within a health economics workshop held by the Pasteur Institute, Vietnam.
- **2016:** Provided lectures and led journal clubs on health economics within the PhD student training programme at the Oxford University Clinical Research Unit.
- **2014-2015:** Lectured on Methods to incorporate age structure into mathematical models in the MSc in Epidemiology course and on **Health Economics & Infectious Disease Modelling** in the Infectious Disease Modelling short course at Imperial College London.

Computer Skills

- Experience in using **R** and **STATA** for statistical analysis.
- Extensive experience in coding dynamic transmission models in **MATLAB** and **R**.

Funding

Funder	Amount	Title	Role	Dates
Wellcome Trust	£3,529,539	Innovative biomedical engineering and computational science to improve the management of critical illness in resource-limited settings	Named collaborator and member of project team: leading the health economic research within the trial.	01/01/2019-01/01/2021
Wellcome Trust	£70,133	Establishing systemic policy engagement at OUCRU: a pilot project	Co-applicant	01/03/19-01/09/20
Global Challenges Research fund	£14,972	Health economics and qualitative research training workshop in Southeast Asia	Principal Investigator	1/11/18-1/06/19
OUCRU – core funding	US\$18,870	Health economics support team: extension for 2018-2019	Principal Investigator	16/11/18-16/11/19
Wellcome Trust	£3,350,722	Collaborative Award in Science, ‘SouthEast Asian Research Collaboration in Hepatitis (SEARCH)’	Named collaborator and member of project team: leading the health economic research within the trial.	01/04/18-01/04/22
MRC	£440,452.89	SEARCH: SouthEast Asian Research Collaborative in Hepatitis	Co-applicant	01/03/17-31/03/19
OUCRU – core funding	US\$54,980	Development of a health economics support unit within OUCRU	Principal Investigator	16/11/16-16/11/18
The Onchocerciasis Vaccine for Africa Initiative	£9,818	Human onchocerciasis: potential long-term consequences of a vaccination programme	Principal Investigator	01/04/13-01/12/13
ESRC	£1,776	Overseas Institutional Visit to the Ghana Health Service	Principal Investigator	01/01/12-15/03/12
ESRC	Full studentship with stipend	PhD studentship	PhD student	01/10/10-01/10/13

Publication Statistics

- **Number of peer-reviewed publications:** 50 (including 21 first author and 3 last author)
- **Number of letters and correspondence articles:** 6 (including 3 first author and 1 last author)
- **Citations:** 1,204
- **h-index:** 23
- **i10-index:** 35

Peer Reviewed Publications

[†: Key papers] [First and last author papers are underlined]

† 50. Mathew, C.G., Bettis, A.A., Chu, B.K., English, M., Ottesen, E.A. Bradley, M.H. and **Turner, H.C.** The health and economic burden of lymphatic filariasis prior to mass drug administration programmes. *Clin Infect Dis, In Press.*

49. Nhan, L.N.T., **Turner, H.C.**, Khanh, H.T., Hung, N.T., Lien, B.L., Thu Hong, N.T., Truc Nhu, L.N., Han Ny., N.T. Nguyet, L.A., Thanh, T.T., Tu Van, H.M., Viet, H.L., Tung, T.H., Thi Phuong, N., Devine, A., Thwaites, G., Vinh Chau, N.V., Thwaites, C.L., van Doorn, H.R. and Tan, LV. Economic Burden Attributed to Hand, Foot and Mouth Disease in Vietnam. *Open Forum Infect Dis, In Press.* [LINK](#).

48. Toor, J., Truscott, J.E., Werkman, M., **Turner, H.C.**, Phillips, A.E., King, C.H., Medley, G.F. and Anderson, R.M. Determining post-treatment surveillance criteria for detecting the elimination of *Schistosoma mansoni* transmission. *Parasit Vectors, In Press.*

47. **Turner, H.C.**, Walker., M., Pion, S.D.S., McFarland, D.A., Bundy, D.A.P. and Basáñez, M.G. Economic evaluations of onchocerciasis interventions: a systematic review and research needs. *Trop Med Int Health, In Press.* [LINK](#).

† 46. **Turner, H.C.**, Lauer, J.A., Bach, X.T., Teerawattananon, Y. and Jit M. Adjusting for inflation and currency changes within health economic studies. *Value in Health, In Press.* [LINK](#).

45. Loan, H.T., Yen, L.M., Kestlyn, E., Hao, N.V., Thanh, T.T., Dung, N.T.P., **Turner, H.C.**, Geskus R., Wolbers, M., Tan, L.C., Doorn, R.V., Day, N.P., Wyncoll, D., Hien, T.T., Thwaites, G.E., Chau, N.V.V. and Thwaites, C.L. Intrathecal Immunoglobulin for treatment of adult patients with tetanus: a randomized controlled 2x2 factorial trial. *Wellcome Open Research, In Press.* [LINK](#).

44. Huong, V.T.L., **Turner, H.C.**, Kinh, N.V. Thai, P.Q., Hoa, N.T., Horby, Doorn, R.V. and Wertheim, H.F.L (2019). Burden of disease and economic impact of human Streptococcus suis infection in Viet Nam. *Trans R Soc Trop Med Hyg. In Press.* [LINK](#).

43. Dat, V.Q., Huong, V.T.L., **Turner, H.C.**, Thwaites, C.L. Doorn, R.V. and Nadjm, B. (2018) Excess direct hospital cost of treating adult patients with ventilator associated respiratory infection (VARI) in Vietnam. *PloS One*, 13(10): e0206760. [LINK](#).

42. Toor, J., **Turner, H.C.**, Truscott, J.E., Werkman, M., Phillips, A.E., Alsallaq, R., Medley, G.F., King, C.H. and Anderson, R.M (2018) The design of schistosomiasis monitoring and evaluation programmes: The importance of collecting adult data to inform treatment strategies for *Schistosoma mansoni*. *PLoS Negl Trop Dis*, 12(10):e0006717. [LINK](#).

† 41. **Turner, H.C.**, Toor, J., Bettis, A.A., Hopkins, A.D., Kyaw, S.S., Onwujekwe, O., Thwaites, G.E., Lubell., Y. and Fitzpatrick, C. Valuing the unpaid contribution of community health volunteers to mass drug administration programs. *Clin Infect Dis, In press.* [LINK](#).

40. Hung, M.T., Clapham, H.E., Bettis, A.A., Cùròng, H.Q., Thwaites, G.E., Wills, B., Boni, M.F. and **Turner, H.C.** The estimates of the health and economic burden of dengue in Vietnam. *Trends Parasitol*, 34(10):904-918. [LINK](#).

39. **Turner, H.C.**, Wills, B., Rahman, M., Cùròng, H.Q., Thwaites, G.E., Boni, M.F. and Clapham, H.E. (2018) Projected costs associated with school-based screening to inform deployment of Dengvaxia: Vietnam as a case study. *Trans R Soc Trop Med Hyg*, try057. [LINK](#).

38. Bundy, D.A.P., Appleby, L., Bradley, M., Croke, K., Hollingsworth, T.D., Pullan, R., **Turner, H.C.** and de Silva, N. (2018) 100 years of Mass Deworming Programmes: a policy perspective from the World Bank's Disease Control Priorities analyses. *Adv Parasitol*, 100:127-154. [LINK](#).
37. Toor, J., Alsallaq, R., Truscott, J.E., **Turner, H.C.**, Werkman, M., Gurarie, D., King, C.H. and Anderson, R.M. (2018) Are we on our way to achieving the 2020 goals for schistosomiasis morbidity control using current WHO guidelines? *Clin Infect Dis*, 66(S4):S245–52. [LINK](#).
36. Gedge, L.M., Bettis, A.A., Bradley, M.H., Hollingsworth, T.D. and **Turner, H.C.** Economic evaluations of Lymphatic Filariasis interventions (2018) A systematic review and research needs. *Parasit Vectors*, 11:75. [LINK](#).
35. Bundy, D.A.P., de Silva, N., Horton, S., Patton, G.C., Schultz, L., Jamison, D.T., **Disease Control Priorities 3 Child and Adolescent Health and Development Authors Group.** (2018) Investment in child and adolescent health and development: key messages from Disease Control Priorities, 3rd Edition. *The Lancet*, 391:687-699. [LINK](#).
- †34. **Turner, H.C.**, Toor, J., Hollingsworth, T.D., and Anderson, R.M. (2018) Economic evaluations of mass drug administration: The importance of economies of scale and scope. *Clin Infect Dis*, 66(8),1298–1303. [LINK](#).
33. Knowles, S.C.L., Sturrock, H.J.W, **Turner, H.C.**, Whitton, J.W., Gower, C.M., Jemu, S., Phillips, A.E., Meite, A., Thomas, B., Kollie, K., Thomas, C., Rebollo, M.P., Styles, B., Clements, M., Fenwick, A., Harrison, W.E. and Fleming, F.M. (2017) Optimizing simple sampling strategies for schistosomiasis surveys in Africa. *PLoS Negl Trop Dis*, 11(5): e0005599. [LINK](#).
32. **Turner, H.C.**, Truscott, J.E., Bettis, A.A., Deol, A.K., Farrell, S.H., Whitton, J.M., Fleming, F.M. and Anderson, R.M (2017). Evaluating the variation in the benefit of community-wide mass treatment for schistosomiasis Implications for future economic evaluations. *Parasit Vectors*, 10: 213. [LINK](#).
- †31. **Turner, H.C.**, Bettis, A.A., Dunn, J.C., Whitton, J.M., Hollingsworth T.D., Fleming, F.M. and Anderson, R.M. (2017) Economic considerations for moving beyond the Kato-Katz technique for diagnosing intestinal parasites as we move towards elimination. *Trends Parasitol*, 33: 435–443. [LINK](#).
30. Truscott, J.E., Gurarie, D., Alsallaq, R., Toor, J., Yoon, N., Farrell, S.H., **Turner, H.C.**, Phillips, A.E., Aurelio, H.O., Ferro, J., King, C.H., and Anderson, R.M (2017). A comparison of two mathematical models of the impact of mass drug administration on the transmission and control of schistosomiasis. *Epidemics*, 18: 29-37. [LINK](#).
29. Anderson, R.M. Farrell, S.H., **Turner, H.C.**, Walson, J., Donnelly, C. and Truscott, J.E. (2017) Assessing the interruption of the transmission of human helminths with mass drug administration alone: optimizing the design of cluster randomised trials. *Parasit Vectors*, 10:93. [LINK](#).
28. Coffeng, L.E*, Truscott, J.E*, Farrell, S.H., **Turner, H.C.**, Sarkar, R., Kang, G., de Vlas, S.J., Anderson, R.M. (2017) Comparison and validation of two mathematical models for the impact of mass drug administration on *Ascaris lumbricoides* and hookworm infection. *Epidemics*, 18: 38-47. [LINK](#).
- †27. **Turner, H.C.**, Bettis, A.A., Chu, B.K., McFarland, D.A., Hooper, P.J., Mante, S.D., Fitzpatrick, C. and Bradley, M.H. (2017) Investment success in public health: An analysis of the cost-effectiveness and cost-benefit of the Global Programme to Eliminate Lymphatic Filariasis. *Clin Infect Dis*, 64: 728-735. [LINK](#).
26. Truscott, J.E., **Turner, H.C.**, Farrell, S.H. and Anderson, R.M. (2016) Soil-Transmitted Helminths: mathematical models of transmission, the impact of mass drug administration and transmission elimination criteria. *Adv Parasitol*, 94: 133–198. [LINK](#).
25. Basáñez, M-G*, Walker, M*, **Turner, H.C.**, Coffeng, L.E., de Vlas, S. and Stolk, W.A. (2016) River Blindness: Mathematical Models for Control and Elimination. *Adv Parasitol*, 94: 247–341. [LINK](#).

24. Medley, G.F., **Turner, H.C.**, Baggaley, R.F., Holland, C. Hollingsworth, T.D. (2016) The Role of More Sensitive Helminth Diagnostics in Mass Drug Administration Campaigns: Elimination and Health Impacts. *Adv Parasitol*, 94:343–392. [LINK](#).
23. Anderson, R.M., **Turner, H.C.**, Farrell, S.H. and Truscott, J.E. (2016) Studies of the transmission dynamics, mathematical model development, and the control of schistosome parasites by mass drug administration in human communities. *Adv Parasitol*, 94:199–246. [LINK](#).
22. Brisson, M., Bénard, E., Drolet, M., Bogaards, J., Baussano, I., Vänskä, S., Jit, M., Boily, M.C., Berkhof, J., Canfell, K., Chesson, H., Burger, E., Choi, Y., De Blasio, B.F., De Vlas, S., Guzzetta, G., Hontelez, J., Horn, J., Jepsen, M., Kim, J., Lazzarato, F., Matthijsse, S., Mikolajczyk, R., Pavelyev, A., Pillsbury, M., Shafer, L.A., Smith, M., Tully, S., **Turner, H.C.**, Usher, C., Walsh, C. (2016) Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models, *Lancet Public Health*, 1(1), e8–e17. [LINK](#).
21. **Turner, H.C.**, Bettis, A.A., Chu, B.K., McFarland, D.A., Hooper, P.J., Ottesen, E.A. and Bradley, M.H. (2016) The Health and Economic Benefits of the Global Programme to Eliminate Lymphatic Filariasis (2000–2014). *Infect Dis Poverty*, 5(1):54. [LINK](#).
20. **Turner, H.C.**, Truscott, J.E., Bettis, A.A., Hollingsworth T.D., Brooker, S.J. and Anderson, R.M. (2016) Analysis of the population-level impact of co-administering ivermectin with albendazole or mebendazole for the control and elimination of *Trichuris trichiura*. *Parasite Epidemiol Control*, 1 (2), 177-187. [LINK](#).
19. Dunn, J.C., **Turner, H.C.**, Tun A. and Anderson, R.M. (2016) Epidemiological surveys of, and research on, the soil-transmitted helminths in Southeast Asia: a systematic review. *Parasit Vectors*, 9:31. [LINK](#).
18. Shuford, K.V., **Turner, H.C.** and Anderson, R.M. (2016) Compliance with anthelmintic treatment in the neglected tropical diseases control programmes: a systematic review. *Parasit Vectors*, 9:29. [LINK](#).
17. **Turner, H.C.**, Truscott, J.E., Fleming, F.M., Hollingsworth T.D., Brooker, S.J. and Anderson, R.M. (2016). Cost-effectiveness of scaling up mass drug administration for the control of soil-transmitted helminths: a comparison of cost function and constant costs analyses. *Lancet Infect Dis*, 16 (7):838-46. [LINK](#).
16. Truscott, J.E., **Turner, H.C.** and Anderson, R.M. (2015) What impact will the achievement of the current World Health Organisation targets for anthelmintic treatment coverage in pre-school aged and school aged children have on the intensity of Soil-Transmitted Helminth infections? *Parasit Vectors*, 8:551. [LINK](#).
15. **Turner, H.C.**, Truscott, J.E., Bettis, A.A., Shuford, K.V., Dunn, J.C., Hollingsworth T.D., Brooker, S.J. and Anderson, R.M. (2015) An economic evaluation of expanding hookworm control strategies to target the whole community. *Parasit Vectors*, 8:570. [LINK](#).
14. Anderson, R.M. **Turner, H.C.**, Farrell, S.H., Yang, J. and Truscott, J.E. (2015) What is required in terms of mass drug administration to interrupt the transmission of schistosome parasites in regions of endemic infection? *Parasit Vectors*, 8:553. [LINK](#).
13. Nikolay, B., Mwandawiro, C.S., Kihara, J.H., Okoyo, C., Cano, J., Mwanje, M.T., Sultani, H., Alusala, D., **Turner, H.C.**, Teti C., Garn, J., Freeman, M.C., Allen, E., Anderson, R.M., Pullan, R.L., Njenga, S.N. and Brooker, S.J. (2015) Understanding heterogeneity in the impact of national neglected tropical disease control programmes: evidence from school-based deworming in Kenya. *PLoS Negl Trop Dis*, 30;9(9):e0004108. [LINK](#).
12. Brooker, S.J., Mwandawiro, C.S., Halliday, K.E., Njenga, S.M., Mcharo, C, Gichuki, P.M., Wasunna, B, Kihara, J.H., Njomo, D., Alusala, D., Chiguzo, A., **Turner, H.C.**, Teti, C, Gwayi-Chore, C., Nikolay, B., Truscott, J E., Hollingsworth, T.D., Balabanova, D., Griffiths, U.K., Freeman, M.C., Allen, E., Pullan, R.L. and Anderson, R.M. (2015) Interrupting transmission of soil-transmitted helminths: a

study protocol for cluster randomised trials evaluating alternative treatment strategies and delivery systems in Kenya. *BMJ OPEN*, 5(10):E008950. [LINK](#).

11. Turner, H.C*, Walker, M*, Lustigman, S., Taylor, D.W. and Basáñez, M.G. (2015) Human onchocerciasis: potential long-term consequences of a vaccination programme. *PLoS Negl Trop Dis*, 17;9(7):e0003938. [LINK](#).

10. Turner, H.C., Truscott, J.E., Hollingsworth T.D., Bettis, A.A., Brooker, S.J. and Anderson, R.M. (2015) Cost and cost-effectiveness of soil-transmitted helminth treatment programmes: systematic review and research needs. *Parasit Vectors*, 3;8:355. [LINK](#).

9. Anderson, R.M., **Turner, H.C.**, Truscott, J.E., Hollingsworth T.D., and Brooker, S.J. (2015) Should the goal for the treatment of Soil Transmitted Helminth (STH) infections be changed from morbidity control in children to community wide transmission elimination? *PLoS Negl Trop Dis*, 9(8): e0003897. [LINK](#).

8. Turner, H.C., Walker, M., Attah, S.K., Opoku, N.O., Awadzi, K., Kuesel, A.C. and Basáñez, M.G. (2015) The potential impact of moxidectin on onchocerciasis elimination in Africa: an economic evaluation based on the Phase II clinical trial data. *Parasit Vectors*, 8:167. [LINK](#).

7. Turner, H.C., Walker, M., French, M.D., Blake, I.M., Churcher, T.S. and Basáñez, M.G. (2014) Neglected tools for neglected diseases: mathematical models in economic evaluations. *Trends Parasitol*, 30(12):562-570. [LINK](#).

†6. Turner, H.C., Walker, M., Churcher, T.S., Osei-Atweneboana, M.Y., Biritwum, N-K., Hopkins, A., Prichard, R.K. and Basáñez, M.G. (2014) Reaching the London Declaration on Neglected Tropical Diseases goals for onchocerciasis: an economic evaluation of increasing the frequency of ivermectin treatment in Africa. *Clin Infect Dis*, 59(7):923-32. [LINK](#).

5. Naidoo, K., Gichuhi, S., Basáñez, M.G., Flaxman, S.R., Jonas, J.B., Keffe, J., Leasher, J.L., Pesudovs, K., Price, H., Smith, J.L., **Turner, H.C.**, White, R.A., Wong, T.Y., Resnikoff, S., Taylor, H.R., Bourne, R.R., Vision Loss Expert Group of the Global Burden of Disease Study. (2014) Prevalence and causes of vision loss in sub-Saharan Africa: 1990-2010. *Br J Ophthalmol*, 98(5):612-8. [LINK](#).

4. Turner, H.C., Walker, M., Churcher, T.S. and Basáñez, M.G. (2014) Modelling the impact of ivermectin on River Blindness and its burden of morbidity and mortality in African savannah: EpiOncho projections. *Parasit Vectors*, 7:241. [LINK](#).

3. Turner, H.C., Osei-Atweneboana, M.Y., Walker, M., Tettevi, E.J., Churcher, T.S. Asiedu, O., Biritwum, N-K. and Basáñez, M.G. (2013) The cost of annual versus biannual community-directed treatment of onchocerciasis with ivermectin: Ghana as a case study. *PLoS Negl Trop Dis*, 7(9):e2452. [LINK](#).

2. Turner, H.C., Baussano, I. and Garnett, G.P. (2013) Vaccinating women previously exposed to human papillomavirus: a cost-effectiveness analysis of the bivalent vaccine. *PLoS ONE*, 8(9):e75552. [LINK](#).

1. Turner, H.C., Churcher, T.S., Walker, M., Prichard, R.K., Osei-Atweneboana, M.Y. and Basáñez, M-G. (2013) Uncertainty surrounding projections of the long-term impact of ivermectin treatment on human onchocerciasis. *PLoS Negl Trop Dis*, 7(4):e2169. [LINK](#).

[Letters, Comments and Correspondence Articles](#)

6. McBride, A., Thuy, D.B., Chau, N.V.V., Thwaites, CL., **Turner, H.C.**, and Hao, N.V. Catastrophic healthcare expenditure due to septic shock and dengue shock in Vietnam. *Trans R Soc Trop Med Hy*, *In press*.

5. Hung, M.T., Wills, B., Clapham, H.E., Yacoub S. and **Turner, H.C.** The uncertainty surrounding the burden of the post-acute consequences of dengue infection. *Trends Parasitol*, *In press*. [LINK](#).

4. **Turner, H.C.**, Hao Van, N., Yacoub, S., Hoang Minh, V., Clifton, D.A., Thwaites, G.E., Dondorp, A.M., Thwaites, C.L. and Chau, N.V.V. Achieving affordable critical care in low-income and middle-income countries. *BMJ Global Health*, *In press*. [LINK](#).
3. Juan Carrique-Mas, J., Van Cuong, N., Truong, B.D., Phu D.H., Phuc, T.M., **Turner, H.C.**, Thwaites, G. and Baker, S. The affordability of antimicrobials for animals and humans at retail in Vietnam: A call for revising pricing policies. *International Journal of Antimicrobial Agents*, *In press*. [LINK](#).
2. **Turner, H.C.**, Thwaites, G.E. and Clapham, H.E. (2018) Vaccine-preventable diseases in lower-middle income countries. *Lancet Infect Dis*, 18(9):937-939. [LINK](#).
1. **Turner, H.C.**, Truscott, J.E. and Anderson, R.M. (2016) Cost-effectiveness of community-wide treatment for helminthiasis. *Lancet Glob Health*, 4(3), e156. [LINK](#).

Publications Under Review

4. Deribe, K., Negussu, N., Newport, M.J., Davey, G. and **Turner, H.C** The Health and Economic Burden of Podoconiosis in Ethiopia. **Under review**.
3. Nguyen Anh, H., Cooke, G.S., Day, J.N., Flower, B., Phuong, L.T., Hung, T.H., Dung, N.T., Khoa, D.B., Hung, L.H., Kestelyn, E., Thwaites, G.E., Chau N.V.V, **Turner, H.C** on behalf of SEARCH Investigators. The direct-medical costs associated with interferon-based treatment for Hepatitis C in Vietnam. **Under review**.
2. Tran, B.X., Nguyen, L.H., **Turner, H.C.**, Thu Vu, G., Nguyen, C.T., Latkin, C., Ho, C. and Ho, R. Economic Evaluation Studies in the Field of HIV/AIDS: Research Development and Scopes Analysis (GAP_{RESEARCH}). **Under review**.
1. Collyer, B.S., **Turner, H.C.**, Hollingsworth T.D. and Keeling, M.J. Vaccination or Mass Drug Administration against Schistosomiasis: a cost-effectiveness comparison. **Under Review**.

Reports and Chapters

2. Montresor, A., **Turner, H.C.**, Oshmann, F., Joseph, S.A., Jankovic, D., Fitzpatrick, C. and Gabrielli, A.F. **Guideline Review Committee: World Health Organization**. Cost of different options for the treatment of individuals infected with soil transmitted helminthiasis.
1. Bundy, DAP., Appleby, L., Bradley, M., Croke, K, Hollingsworth, T.D., Pullan, R., **Turner, H.C.** and de Silva, N. Mass Deworming Programs in Middle Childhood and Adolescence, Disease Control Priorities, Third Edition (Volume 8): Child and Adolescent Health and Development, pp.165-182.

Conference and Meeting Oral Presentations (Lead Presenter)

21. **8th ASEAN Congress of Tropical Medicine and Parasitology**: “*The estimates of the health and economic burden of Dengue in Vietnam*”. Held in Nha Trang, Vietnam, July 2018.
20. **NTD Modelling Consortium 2018 Meeting**: “*Health economics and NTDs*”. Held in Warwick, UK, February 2018.
19. **All-Party Parliamentary Group for Malaria and NTDs - Translating NTD Research into Policy event**: “*Health economic research and NTDs*”. Held in London, UK, February 2018.
18. **Health economics and Wolbachia Meeting**: “*Lessons from the filariasis elimination program and dengue in Vietnam*.” Held in Singapore, June 2017.
17. **NTD Modelling Consortium 2017 Meeting**: “*Incorporating costs into economic evaluations of NTD interventions*”. Held in Warwick, UK, March 2017.

16. Liverpool School of Tropical Medicine – Invited Health Economics Seminar: “*Changing our control strategies against intestinal parasites: Cost and cost-effectiveness considerations.*” Held in Liverpool, UK, February 2017.

15. ASTMH 65st Annual Meeting: “*Evaluating the impact and cost-effectiveness of community-wide mass treatment for schistosomiasis – no simple answer*” Held in Atlanta, USA, November 2016.

14. Guideline Review Committee: World Health Organization: “*Cost of different options for the treatment of individuals infected with soil transmitted helminthiasis*”. Held in Geneva, Switzerland, April 2016.

13. British Society for Parasitology Spring Meeting: “*What impact will the current WHO treatment coverage targets have on soil transmitted helminth infections and can a change in strategy break transmission?*”. Held in London, UK, April 2016.

12. London Centre for Neglected Tropical Disease Research Three-Year Anniversary Event: “*Health economics and NTDs*” Held in London, UK, January 2016.

11. ASTMH 64st Annual Meeting: “*An economic evaluation of expanding hookworm control strategies to target the whole community*”. Held in Philadelphia, USA, November 2015

10. Diagnostics Modelling Consortium Meeting (Gates Foundation): “*Cost and health economic considerations for moving beyond the Kato Katz test*”. Held in Seattle, USA, February 2015.

9. NTD Modelling Consortium 2014 Meeting: “*The potential impact of moxidectin on onchocerciasis elimination in Africa: an economic evaluation based on the Phase II clinical trial data*”. Held in New Orleans, USA, November 2014.

8. Trans-Atlantic Product Development Partnership for a River Blindness Vaccine: Update Meeting: “*Human onchocerciasis: potential long-term consequences of vaccination programmes*”. Held in Washington, USA, November 2013.

7. NTD Modelling Consortium 2013 Meeting: “*An economic evaluation of increasing the frequency of ivermectin treatment for onchocerciasis control in Africa*”. Held in Washington, USA, November 2013.

6. ASTMH 62st Annual Meeting: “*An economic evaluation of increasing the frequency of ivermectin treatment for onchocerciasis control in Africa*”. Held in Washington, USA, November 2013.

5. Mectizan Donation Program: Suboptimal Response Meeting: “*The role of coverage and compliance, and drug effects on model projections*”. Held in Accra, Ghana, April 2013.

4. Mectizan Donation Program: Suboptimal Response Meeting: “*Is the current strategy of annual ivermectin distribution appropriate? Comparisons with biannual treatment*”. Held in Accra, Ghana, April 2013.

3. British Society for Parasitology Spring Meeting: “*Uncertainty surrounding projections of the long-term impact of ivermectin treatment for human Onchocerciasis*”. Held in Glasgow, Scotland, April 2012.

2. Royal Society of Tropical Medicine and Hygiene Research in Progress Meeting: “*Projecting the long-term impact of ivermectin treatment on human onchocerciasis: The importance of modelling assumptions*”. Held in London, England, December 2011.

1. DIMACS-Workshop on Genetics and Disease Control: “*Cost-Effectiveness Analyses of Drug Resistance Management Strategies for River Blindness*”. Held in Elmina, Ghana, August 2011.

[Press Releases and News Articles About My Work](#)

GPELF measures cost effective for lymphatic filariasis

PharmacoEconomics & Outcomes News 769, p15 - 14 Jan 2017

Increasing river blindness treatment to twice a year doesn't double cost
[http://www3.imperial.ac.uk/newsandeventspggrp/imperialcollege/newssummary/news_19-9-2013-15-52-2]

HPV Vaccination Worthwhile In Women Over Age 25
[<http://www.healthylivingmagazine.us/Articles/2673/>]

Referees

Available upon request.